About Science Partnerships News Careers Contact Partnerships Open-Innovation Strategy HiFiBiO Therapeutics is committed to working with leading pharmaceutical and biotechnology companies, as well as academic and research institutions to rapidly advance high-quality innovative therapies that can address the unmet medical needs of patients around the world. Areas of Interest Our team is fully committed to open innovation. Our lead assets are open for partnerships in clinical studies. We are also applying our differentiated single-cell profiling capabilities to address pain points in the clinical development of novel therapeutics. Our industry leading proprietary CelliGOTM platform and unique DISTM capabilities offer novel pathways for accelerating the discovery and development of high-quality therapeutic antibodies. They also enable biomarker discovery for advanced patient stratification and enhanced probability of clinical success. We are currently working with several pharma partners to discover and validate novel therapeutic targets, and to identify rare functional antibodies against particularly complex targets. Read our article in Drug Discovery Today for more information on our open-innovation strategy Contact us today to learn more about our open-innovation strategies and partnerships Full Name Company Name Email Country Select your Country United States France China Afghanistan Albania Algeria American Samoa Andorra Angola Antigua and Barbuda Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Colombia Comoros Congo, Democratic Republic of the Congo, Republic of the Costa Rica Côte d'Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Faroe Islands Fiji Finland France French Polynesia Gabon Gambia Georgia Germany Ghana Greece Greenland Grenada Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Micronesia Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Zealand Nicaragua Niger Nigeria Northern Mariana Islands Norway Oman Pakistan Palau Palestine, State of Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Romania Russia Rwanda Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon Islands Somalia South Africa Spain Sri Lanka Sudan Sudan, South Suriname Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands, British Virgin Islands, U.S. Yemen Zambia Zimbabwe Area of Interest Make a Selection Antibody Discovery Biomarker Discovery Licensing Opportunity Novel Target Discovery Open Innovation Lab Job Opportunities Your message By submitting this form you agree to our Privacy Policy. We welcome inquiries from prospective partners interested in Pipeline Partnering our advanced immunomodulatory programs for joint IND filings and/or clinical trials Identifying innovative ideas for novel targeting and immunomodulation mechanisms Exploring innovative technologies and platforms that help generate the best therapeutic molecules Single-cell platform technologies Discovering and validating novel targets for antibodies or other therapeutic approaches Generating high quality therapeutic antibodies against targets of interest, including functional antibodies against complex targets (e.g. GPCRs, ion channels) Discovering and validating biomarkers for patient stratification through our DISTM platform Further advancing our single-cell platform through other enabling applications and technologies Discovering therapeutics and tool antibodies from patient samples Profiling tumor microenvironment Other Areas Developing emerging technologies for antibody therapeutics Boosting big data analysis/processing capabilities through specialized AI/machine learning platforms Partnership Highlights Previous Kite and HiFiBio Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia Read More Research Collaboration to Develop Technology for the Treatment of Cancer Read More Research Collaboration to Develop Technology for the Treatment of Cancer Read More Next Ready for the next steps? Contact us to learn more Contact Us About Science Partnerships News Careers Contact © HiFiBiO Therapeutics, 2021. All Rights Reserved. Privacy Policy Manage cookie settings